The Safety and Feasibility of Intra Surgical Cavity or intra Cerebrospinal Fluid (CSF) Injection of Haploidentical Activated NK Cells in Patients with Recurrent Glioblastoma Multiforme and Brain Tumors

Despite multi-modal therapies for patients with malignant brain tumors, their median survival is < 2 year. Recently, NK cells provided to cancer immune surveillance through their direct natural cytotoxicity, by modulating dendritic cells to enhance the presentation of tumor antigens and regulating T-cell mediated antitumor responses. However, the success of this treatment modality in brain tumors is unclear. The main reasons are the brain tumor microenvironment, approach of NK cell preparation and administration and the donor selection. Our, previous study showed that intracranial injection of activated haploidentical NK cells resulted in the eradication of glioblastoma tumor masses in the animal model. The animals had no evidence of tumor recurrence after treatment, and all tumor-related complications resolved after treatment. Therefore, in the present study, we evaluated the safety of intra surgical cavity or intra cerebrospinal fluid (CSF) Injection of ex vivo activated haploidentical NK cells in six patients with recurrent glioblastoma multiform (GBM) and malignant brain tumors resistance to chemo/radio therapy. The results showed that local administration of the haploidentical NK cells in malignant brain tumors is safe, feasible, tolerated at higher dose and also is cost effective.